Wolverine Asset Management LLC Affimed N.V. Transaction History

Wolverine Asset Management LLC

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2019 Nov 14, 2019	SELL	$2.67 - $3.65 $534,000 - $730,000	-200,000 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$2.6 - $4.21 $520,000 - $842,000	200,000 New	200,000 $574,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Wolverine Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Wolverine Asset Management LLC with notifications on news.